Seed Health, a company working in microbiome science, has unveiled promising clinical data on their flagship product, VS-01 Vaginal Synbiotic. The findings will be presented at the 2024 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG). This study is the first to demonstrate that a multi-strain vaginal synbiotic can successfully establish a protective and optimal vaginal microbiome, dominated by Lactobacillus crispatus, which is known to reduce harmful microbes and combat vaginal dysbiosis, according to the company
Dr. Jacques Ravel, a renowned vaginal microbiome researcher, shares: “Over more than two decades of research, we have elucidated the critical role of Lactobacillus crispatus in maintaining a protective and stable vaginal microbiome and identified specific strains that are particularly effective at promoting vaginal health. VS-01 was formulated using a consortia design with three proprietary strains of L. crispatus to successfully establish an L. crispatus-dominant vaginal microbiome, marking a significant milestone in the field and advancement for women’s health.”
The randomized, placebo-controlled clinical trial demonstrated that VS-01 significantly outperforms other formats, including placebo and leading oral probiotics for vaginal health. The study revealed that 90% of participants using VS-01™ established an optimal vaginal microbiome within 21 days, compared to only 11% in the placebo group. The success of VS-01 is attributed to Seed’s proprietary SMART Tablet technology, which offers an extended-release profile ensuring superior conversion to an L. crispatus-dominant microbiome.
Sheri Simmons, Ph.D., VP of Discovery at Seed Health, highlighted: “VS-01™ was developed to set a new standard in vaginal care. Our latest clinical findings underscore the potential of proactive care centered on the vaginal microbiome. By modulating the vaginal ecology, VS-01™ offers a new approach to support long-term vaginal health.”
Further reinforcing the benefits of VS-01, a poster presentation at IDSOG detailed its efficacy in reducing inflammation and harmful microbes. The study showed that VS-01 significantly lowered levels of the inflammatory cytokine IL-1alpha and reduced the abundance of Candida spp. and Gardnerella, which are often associated with vaginal dysbiosis and inflammation. Additionally, VS-01 was shown to decrease mucin-degrading sialidase genes, suggesting an improvement in the protective mucus barrier.
Dirk Gevers, Ph.D., Chief Scientific Officer at Seed Health, stated: “The data presented at IDSOG showcases the rigorous scientific approach we bring to probiotics and microbiome-directed solutions. By evaluating biomarkers of vaginal health and conducting deep microbiome sequencing, we have validated the clinical benefits of VS-01 to clearly distinguish it from other vaginal health solutions.”
Seed Health’s consumer brand Seed, is known for clinically validated probiotics such as DS-01 Daily Synbiotic and PDS-08 Pediatric Daily Synbiotic. Seed Health’s pipeline includes applications for gastrointestinal and digestive health, women’s health, skin, pediatrics, brain health, metabolic function, and healthy aging.
